{"id":5,"date":"2022-07-20T18:05:12","date_gmt":"2022-07-20T18:05:12","guid":{"rendered":"https:\/\/palynziqhcp-dev-001.azurewebsites.net\/en-us\/palynziq\/?page_id=5"},"modified":"2024-06-12T13:41:07","modified_gmt":"2024-06-12T13:41:07","slug":"palynziq-for-pku","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/","title":{"rendered":"PALYNZIQ for PKU"},"content":{"rendered":"
PALYNZIQ\u00ae<\/sup> (pegvaliase-pqpz) Injection gives eligible adult patients the chance to see blood Phe levels below 360 \u03bcmol\/L1<\/sup><\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n Discover long-term efficacy and safety data out to 3 years<\/p>\n\n\n\n \n <\/div>\n ACMG recommends maintaining blood Phe levels below\u00a0360 \u03bcmol\/L (6 mg\/dL)\u00a0for patients with PKU2<\/sup><\/p>\n
\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n
PALYNZIQ Clinical Trial Results\n<\/h4>\n \n \n\n